| 1 |
Ostrom QT, Price M, Neff C, Cioffi G, Waite KA, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the united states in 2015-2019. Neuro Oncol, 2022, 24(Suppl 5): v1- v95.
|
| 2 |
Jiang T, Mao Y, Ma W, Mao Q, You Y, Yang X, Jiang C, Kang C, Li X, Chen L, Qiu X, Wang W, Li W, Yao Y, Li S, Li S, Wu A, Sai K, Bai H, Li G, Chen B, Yao K, Wei X, Liu X, Zhang Z, Dai Y, Lv S, Wang L, Lin Z, Dong J, Xu G, Ma X, Cai J, Zhang W, Wang H, Chen L, Zhang C, Yang P, Yan W, Liu Z, Hu H, Chen J, Liu Y, Yang Y, Wang Z, Wang Z, Wang Y, You G, Han L, Bao Z, Liu Y, Wang Y, Fan X, Liu S, Liu X, Wang Y, Wang Q, Chinese Glioma Cooperative Group (CGCG). CGCG clinical practice guidelines for the management of adult diffuse gliomas. Cancer Lett, 2016, 375: 263- 273.
doi: 10.1016/j.canlet.2016.01.024
|
| 3 |
Weller M, Wen PY, Chang SM, Dirven L, Lim M, Monje M, Reifenberger G. Glioma. Nat Rev Dis Primers, 2024, 10: 33.
doi: 10.1038/s41572-024-00516-y
|
| 4 |
Hambardzumyan D, Bergers G. Glioblastoma: defining tumor niches. Trends Cancer, 2015, 1: 252- 265.
doi: 10.1016/j.trecan.2015.10.009
|
| 5 |
White K, Connor K, Meylan M, Bougoüin A, Salvucci M, Bielle F, O'Farrell AC, Sweeney K, Weng L, Bergers G, Dicker P, Ashley DM, Lipp ES, Low JT, Zhao J, Wen P, Prins R, Verreault M, Idbaih A, Biswas A, Prehn JHM, Lambrechts D, Arijs I, Lodi F, Dilcan G, Lamfers M, Leenstra S, Fabro F, Ntafoulis I, Kros JM, Cryan J, Brett F, Quissac E, Beausang A, MacNally S, O'Halloran P, Clerkin J, Bacon O, Kremer A, Chi Yen RT, Varn FS, Verhaak RGW, Sautès-Fridman C, Fridman WH, Byrne AT. Identification, validation and biological characterisation of novel glioblastoma tumour microenvironment subtypes: implications for precision immunotherapy. Ann Oncol, 2023, 34: 300- 314.
doi: 10.1016/j.annonc.2022.11.008
|
| 6 |
De Silva MI, Stringer BW, Bardy C. Neuronal and tumourigenic boundaries of glioblastoma plasticity. Trends Cancer, 2023, 9: 223- 236.
doi: 10.1016/j.trecan.2022.10.010
|
| 7 |
Yu K, Hu Y, Wu F, Guo Q, Qian Z, Hu W, Chen J, Wang K, Fan X, Wu X, Rasko JE, Fan X, Iavarone A, Jiang T, Tang F, Su XD. Surveying brain tumor heterogeneity by single-cell RNA-sequencing of multi-sector biopsies. Natl Sci Rev, 2020, 7: 1306- 1318.
doi: 10.1093/nsr/nwaa099
|
| 8 |
Koh L, Novera W, Lim SW, Chong YK, Pang QY, Low D, Ang BT, Tang C. Integrative multi-omics approach to targeted therapy for glioblastoma. Pharmacol Res, 2022, 182: 106308.
doi: 10.1016/j.phrs.2022.106308
|
| 9 |
Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K, Dewar K, Doyle M, FitzHugh W, Funke R, Gage D, Harris K, Heaford A, Howland J, Kann L, Lehoczky J, LeVine R, McEwan P, McKernan K, Meldrim J, Mesirov JP, Miranda C, Morris W, Naylor J, Raymond C, Rosetti M, Santos R, Sheridan A, Sougnez C, Stange-Thomann Y, Stojanovic N, Subramanian A, Wyman D, Rogers J, Sulston J, Ainscough R, Beck S, Bentley D, Burton J, Clee C, Carter N, Coulson A, Deadman R, Deloukas P, Dunham A, Dunham I, Durbin R, French L, Grafham D, Gregory S, Hubbard T, Humphray S, Hunt A, Jones M, Lloyd C, McMurray A, Matthews L, Mercer S, Milne S, Mullikin JC, Mungall A, Plumb R, Ross M, Shownkeen R, Sims S, Waterston RH, Wilson RK, Hillier LW, McPherson JD, Marra MA, Mardis ER, Fulton LA, Chinwalla AT, Pepin KH, Gish WR, Chissoe SL, Wendl MC, Delehaunty KD, Miner TL, Delehaunty A, Kramer JB, Cook LL, Fulton RS, Johnson DL, Minx PJ, Clifton SW, Hawkins T, Branscomb E, Predki P, Richardson P, Wenning S, Slezak T, Doggett N, Cheng JF, Olsen A, Lucas S, Elkin C, Uberbacher E, Frazier M, Gibbs RA, Muzny DM, Scherer SE, Bouck JB, Sodergren EJ, Worley KC, Rives CM, Gorrell JH, Metzker ML, Naylor SL, Kucherlapati RS, Nelson DL, Weinstock GM, Sakaki Y, Fujiyama A, Hattori M, Yada T, Toyoda A, Itoh T, Kawagoe C, Watanabe H, Totoki Y, Taylor T, Weissenbach J, Heilig R, Saurin W, Artiguenave F, Brottier P, Bruls T, Pelletier E, Robert C, Wincker P, Smith DR, Doucette-Stamm L, Rubenfield M, Weinstock K, Lee HM, Dubois J, Rosenthal A, Platzer M, Nyakatura G, Taudien S, Rump A, Yang H, Yu J, Wang J, Huang G, Gu J, Hood L, Rowen L, Madan A, Qin S, Davis RW, Federspiel NA, Abola AP, Proctor MJ, Myers RM, Schmutz J, Dickson M, Grimwood J, Cox DR, Olson MV, Kaul R, Raymond C, Shimizu N, Kawasaki K, Minoshima S, Evans GA, Athanasiou M, Schultz R, Roe BA, Chen F, Pan H, Ramser J, Lehrach H, Reinhardt R, McCombie WR, de la Bastide M, Dedhia N, Blöcker H, Hornischer K, Nordsiek G, Agarwala R, Aravind L, Bailey JA, Bateman A, Batzoglou S, Birney E, Bork P, Brown DG, Burge CB, Cerutti L, Chen HC, Church D, Clamp M, Copley RR, Doerks T, Eddy SR, Eichler EE, Furey TS, Galagan J, Gilbert JG, Harmon C, Hayashizaki Y, Haussler D, Hermjakob H, Hokamp K, Jang W, Johnson LS, Jones TA, Kasif S, Kaspryzk A, Kennedy S, Kent WJ, Kitts P, Koonin EV, Korf I, Kulp D, Lancet D, Lowe TM, McLysaght A, Mikkelsen T, Moran JV, Mulder N, Pollara VJ, Ponting CP, Schuler G, Schultz J, Slater G, Smit AF, Stupka E, Szustakowki J, Thierry-Mieg D, Thierry-Mieg J, Wagner L, Wallis J, Wheeler R, Williams A, Wolf YI, Wolfe KH, Yang SP, Yeh RF, Collins F, Guyer MS, Peterson J, Felsenfeld A, Wetterstrand KA, Patrinos A, Morgan MJ, de Jong P, Catanese JJ, Osoegawa K, Shizuya H, Choi S, Chen YJ, Szustakowki J, International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature, 2001, 409: 860- 921.
doi: 10.1038/35057062
|
| 10 |
|
| 11 |
Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol, 2021, 23: 1231- 1251.
doi: 10.1093/neuonc/noab106
|
| 12 |
Yang XJ, Yin HF, Li Z, Yu SZ. Chinese version of simplified table of 2021 WHO Classification of Tumors of the Central Nervous System (fifth edition) and translational interpretations. Zhongguo Xian Dai Shen Jing Ji Bing Za Zhi, 2021, 21: 746- 750.
doi: 10.3969/j.issn.1672-6731.2021.09.004
|
|
杨学军, 尹洪芳, 李智, 于士柱. 2021年世界卫生组织中枢神经系统肿瘤分类(第五版)简表中译版及说明. 中国现代神经疾病杂志, 2021, 21: 746- 750.
doi: 10.3969/j.issn.1672-6731.2021.09.004
|
| 13 |
Dakal TC, Kakde GS, Maurya PK. Genomic, epigenomic and transcriptomic landscape of glioblastoma. Metab Brain Dis, 2024, 39: 1591- 1611.
doi: 10.1007/s11011-024-01414-8
|
| 14 |
Familiari P, Lapolla P, Picotti V, Palmieri M, Pesce A, Carosi G, Relucenti M, Nottola S, Gianno F, Minasi S, Antonelli M, Frati A, Santoro A, D'Andrea G, Bruzzaniti P, LA Pira B. Role of 1p/19q codeletion in diffuse low-grade glioma tumour prognosis. Anticancer Res, 2023, 43: 2659- 2670.
doi: 10.21873/anticanres.16432
|
| 15 |
Pacesa M, Pelea O, Jinek M. Past, present, and future of CRISPR genome editing technologies. Cell, 2024, 187: 1076- 1100.
doi: 10.1016/j.cell.2024.01.042
|
| 16 |
Qu J, Qiu B, Zhang Y, Hu Y, Wang Z, Guan Z, Qin Y, Sui T, Wu F, Li B, Han W, Peng X. The tumor-enriched small molecule gambogic amide suppresses glioma by targeting WDR1-dependent cytoskeleton remodeling. Signal Transduct Target Ther, 2023, 8: 424.
doi: 10.1038/s41392-023-01666-3
|
| 17 |
Król ZJ, Dobosz P, Ślubowska A, Mroczek M. WGS data collections: how do genomic databases transform medicine. Int J Mol Sci, 2023, 24: 3031.
doi: 10.3390/ijms24033031
|
| 18 |
Wu M, Wang T, Ji N, Lu T, Yuan R, Wu L, Zhang J, Li M, Cao P, Zhao J, Li G, Li J, Li Y, Tang Y, Gao Z, Wang X, Cheng W, Ge M, Cui G, Li R, Wu A, You Y, Zhang W, Wang Q, Chen J. Multi-omics and pharmacological characterization of patient-derived glioma cell lines. Nat Commun, 2024, 15: 6740.
doi: 10.1038/s41467-024-51214-y
|
| 19 |
Dubois FPB, Shapira O, Greenwald NF, Zack T, Wala J, Tsai JW, Crane A, Baguette A, Hadjadj D, Harutyunyan AS, Kumar KH, Blattner-Johnson M, Vogelzang J, Sousa C, Kang KS, Sinai C, Wang DK, Khadka P, Lewis K, Nguyen L, Malkin H, Ho P, O'Rourke R, Zhang S, Gold R, Deng D, Serrano J, Snuderl M, Jones C, Wright KD, Chi SN, Grill J, Kleinman CL, Goumnerova LC, Jabado N, Jones DTW, Kieran MW, Ligon KL, Beroukhim R, Bandopadhayay P. Structural variants shape driver combinations and outcomes in pediatric high-grade glioma. Nat Cancer, 2022, 3: 994- 1011.
doi: 10.1038/s43018-022-00403-z
|
| 20 |
Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, Williams PM, Modrusan Z, Feuerstein BG, Aldape K. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell, 2006, 9: 157- 173.
doi: 10.1016/j.ccr.2006.02.019
|
| 21 |
Munquad S, Das AB. DeepAutoGlioma: a deep learning autoencoder-based multi-omics data integration and classification tools for glioma subtyping. BioData Min, 2023, 16: 32.
doi: 10.1186/s13040-023-00349-7
|
| 22 |
Neftel C, Laffy J, Filbin MG, Hara T, Shore ME, Rahme GJ, Richman AR, Silverbush D, Shaw ML, Hebert CM, Dewitt J, Gritsch S, Perez EM, Gonzalez Castro LN, Lan X, Druck N, Rodman C, Dionne D, Kaplan A, Bertalan MS, Small J, Pelton K, Becker S, Bonal D, Nguyen QD, Servis RL, Fung JM, Mylvaganam R, Mayr L, Gojo J, Haberler C, Geyeregger R, Czech T, Slavc I, Nahed BV, Curry WT, Carter BS, Wakimoto H, Brastianos PK, Batchelor TT, Stemmer-Rachamimov A, Martinez-Lage M, Frosch MP, Stamenkovic I, Riggi N, Rheinbay E, Monje M, Rozenblatt-Rosen O, Cahill DP, Patel AP, Hunter T, Verma IM, Ligon KL, Louis DN, Regev A, Bernstein BE, Tirosh I, Suvà ML. An integrative model of cellular states, plasticity, and genetics for glioblastoma. Cell, 2019, 178: 835- 849.
doi: 10.1016/j.cell.2019.06.024
|
| 23 |
Couturier CP, Ayyadhury S, Le PU, Nadaf J, Monlong J, Riva G, Allache R, Baig S, Yan X, Bourgey M, Lee C, Wang YCD, Wee Yong V, Guiot MC, Najafabadi H, Misic B, Antel J, Bourque G, Ragoussis J, Petrecca K. Single-cell RNA-seq reveals that glioblastoma recapitulates a normal neurodevelopmental hierarchy. Nat Commun, 2020, 11: 3406.
doi: 10.1038/s41467-020-17186-5
|
| 24 |
Yeo AT, Rawal S, Delcuze B, Christofides A, Atayde A, Strauss L, Balaj L, Rogers VA, Uhlmann EJ, Varma H, Carter BS, Boussiotis VA, Charest A. Single-cell RNA sequencing reveals evolution of immune landscape during glioblastoma progression. Nat Immunol, 2022, 23: 971- 984.
doi: 10.1038/s41590-022-01215-0
|
| 25 |
Ramani A, Pasquini G, Gerkau NJ, Jadhav V, Vinchure OS, Altinisik N, Windoffer H, Muller S, Rothenaigner I, Lin S, Mariappan A, Rathinam D, Mirsaidi A, Goureau O, Ricci-Vitiani L, D'Alessandris QG, Wollnik B, Muotri A, Freifeld L, Jurisch-Yaksi N, Pallini R, Rose CR, Busskamp V, Gabriel E, Hadian K, Gopalakrishnan J. Reliability of high-quantity human brain organoids for modeling microcephaly, glioma invasion and drug screening. Nat Commun, 2024, 15: 10703.
doi: 10.1038/s41467-024-55226-6
|
| 26 |
Xu X, Zheng Y, Luo L, You Z, Chen H, Wang J, Zhang F, Liu Y, Ke Y. Glioblastoma stem cells deliver ABCB4 transcribed by ATF3 via exosomes conferring glioblastoma resistance to temozolomide. Cell Death Dis, 2024, 15: 318.
doi: 10.1038/s41419-024-06695-6
|
| 27 |
Meyer N, Zielke S, Michaelis JB, Linder B, Warnsmann V, Rakel S, Osiewacz HD, Fulda S, Mittelbronn M, Münch C, Behrends C, Kögel D. AT 101 induces early mitochondrial dysfunction and HMOX1(heme oxygenase 1) to trigger mitophagic cell death in glioma cells. Autophagy, 2018, 14: 1693- 1709.
doi: 10.1080/15548627.2018.1476812
|
| 28 |
Kim KH, Migliozzi S, Koo H, Hong JH, Park SM, Kim S, Kwon HJ, Ha S, Garofano L, Oh YT, D'Angelo F, Kim CI, Kim S, Lee JY, Kim J, Hong J, Jang EH, Mathon B, Di Stefano AL, Bielle F, Laurenge A, Nesvizhskii AI, Hur EM, Yin J, Shi B, Kim Y, Moon KS, Kwon JT, Lee SH, Lee SH, Gwak HS, Lasorella A, Yoo H, Sanson M, Sa JK, Park CK, Nam DH, Iavarone A, Park JB. Integrated proteogenomic characterization of glioblastoma evolution. Cancer Cell, 2024, 42: 358- 377.
doi: 10.1016/j.ccell.2023.12.015
|
| 29 |
Duhamel M, Drelich L, Wisztorski M, Aboulouard S, Gimeno JP, Ogrinc N, Devos P, Cardon T, Weller M, Escande F, Zairi F, Maurage CA, Le Rhun É, Fournier I, Salzet M. Spatial analysis of the glioblastoma proteome reveals specific molecular signatures and markers of survival. Nat Commun, 2022, 13: 6665.
doi: 10.1038/s41467-022-34208-6
|
| 30 |
Shen L, Zhang Z, Wu P, Yang J, Cai Y, Chen K, Chai S, Zhao J, Chen H, Dai X, Yang B, Wei W, Dong L, Chen J, Jiang P, Cao C, Ma C, Xu C, Zou Y, Zhang J, Xiong W, Li Z, Xu S, Shu B, Wang M, Li Z, Wan Q, Xiong N, Chen S. Mechanistic insight into glioma through spatially multidimensional proteomics. Sci Adv, 2024, 10: eadk1721.
doi: 10.1126/sciadv.adk1721
|
| 31 |
Chen X, Bertho G, Caradeuc C, Giraud N, Lucas-Torres C. Present and future of pure shift NMR in metabolomics. Magn Reson Chem, 2023, 61: 654- 673.
doi: 10.1002/mrc.5356
|
| 32 |
Yu S, Zou Y, Ma X, Wang D, Luo W, Tang Y, Mu D, Zhang R, Cheng X, Qiu L. Evolution of LC-MS/MS in clinical laboratories. Clin Chim Acta, 2024, 555: 117797.
doi: 10.1016/j.cca.2024.117797
|
| 33 |
Venneti S, Thompson CB. Metabolic reprogramming in brain tumors. Annu Rev Pathol, 2017, 12: 515- 545.
doi: 10.1146/annurev-pathol-012615-044329
|
| 34 |
Cortes Ballen AI, Amosu M, Ravinder S, Chan J, Derin E, Slika H, Tyler B. Metabolic reprogramming in glioblastoma multiforme: a review of pathways and therapeutic targets. Cells, 2024, 13: 1574.
doi: 10.3390/cells13181574
|
| 35 |
Li G, Wang D, Zhai Y, Pan C, Zhang J, Wang C, Huang R, Yu M, Li Y, Liu X, Liu Y, Wu F, Zhao Z, Hu H, Shi Z, Kahlert UD, Jiang T, Zhang W. Glycometabolic reprogramming-induced XRCC1 lactylation confers therapeutic resistance in ALDH1A3-overexpressing glioblastoma. Cell Metab, 2024, 36: 1696- 1710.
doi: 10.1016/j.cmet.2024.07.011
|
| 36 |
Rudà R, Horbinski C, van den Bent M, Preusser M, Soffietti R. IDH inhibition in gliomas: from preclinical models to clinical trials. Nat Rev Neurol, 2024, 20: 395- 407.
doi: 10.1038/s41582-024-00967-7
|
| 37 |
Perelroizen R, Philosof B, Budick-Harmelin N, Chernobylsky T, Ron A, Katzir R, Shimon D, Tessler A, Adir O, Gaoni-Yogev A, Meyer T, Krivitsky A, Shidlovsky N, Madi A, Ruppin E, Mayo L. Astrocyte immunometabolic regulation of the tumour microenvironment drives glioblastoma pathogenicity. Brain, 2022, 145: 3288- 3307.
doi: 10.1093/brain/awac222
|
| 38 |
Guo D, Tong Y, Jiang X, Meng Y, Jiang H, Du L, Wu Q, Li S, Luo S, Li M, Xiao L, He H, He X, Yu Q, Fang J, Lu Z. Aerobic glycolysis promotes tumor immune evasion by hexokinase 2-mediated phosphorylation of IκBα. Cell Metab, 2022, 34: 1312- 1324.
doi: 10.1016/j.cmet.2022.08.002
|
| 39 |
Garrett MC, Albano R, Carnwath T, Shah S, Woo D, Lamba M, Plas DR, Paranjpe A, Roskin K, Zhao C, Lu R. Chromatin structure predicts survival in glioma patients. Sci Rep, 2022, 12: 8221.
doi: 10.1038/s41598-022-11019-9
|
| 40 |
Ravi VM, Will P, Kueckelhaus J, Sun N, Joseph K, Salié H, Vollmer L, Kuliesiute U, von Ehr J, Benotmane JK, Neidert N, Follo M, Scherer F, Goeldner JM, Behringer SP, Franco P, Khiat M, Zhang J, Hofmann UG, Fung C, Ricklefs FL, Lamszus K, Boerries M, Ku M, Beck J, Sankowski R, Schwabenland M, Prinz M, Schüller U, Killmer S, Bengsch B, Walch AK, Delev D, Schnell O, Heiland DH. Spatially resolved multi-omics deciphers bidirectional tumor-host interdependence in glioblastoma. Cancer Cell, 2022, 40: 639- 655.
doi: 10.1016/j.ccell.2022.05.009
|
| 41 |
Alejo S, Palacios BE, Venkata PP, He Y, Li W, Johnson JD, Chen Y, Jayamohan S, Pratap UP, Clarke K, Zou Y, Lv Y, Weldon K, Viswanadhapalli S, Lai Z, Ye Z, Chen Y, Gilbert AR, Suzuki T, Tekmal RR, Zhao W, Zheng S, Vadlamudi RK, Brenner AJ, Sareddy GR. Lysine-specific histone demethylase 1A (KDM1A/LSD1) inhibition attenuates DNA double-strand break repair and augments the efficacy of temozolomide in glioblastoma. Neuro Oncol, 2023, 25: 1249- 1261.
doi: 10.1093/neuonc/noad018
|
| 42 |
Hu H, Mu Q, Bao Z, Chen Y, Liu Y, Chen J, Wang K, Wang Z, Nam Y, Jiang B, Sa JK, Cho HJ, Her NG, Zhang C, Zhao Z, Zhang Y, Zeng F, Wu F, Kang X, Liu Y, Qian Z, Wang Z, Huang R, Wang Q, Zhang W, Qiu X, Li W, Nam DH, Fan X, Wang J, Jiang T. Mutational landscape of secondary glioblastoma guides MET-targeted trial in brain tumor. Cell, 2018, 175: 1665- 1678.
doi: 10.1016/j.cell.2018.09.038
|
| 43 |
Liu Y, Wu M. Deep learning in precision medicine and focus on glioma. Bioeng Transl Med, 2023, 8: e10553.
doi: 10.1002/btm2.10553
|